Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Investigating autoreactive B cells in autoimmune diseases vs recall tetanus toxoid response
2024-515312-50-00Phase 4Authorised
- Sponsor
- Leiden University Medical Center
- Start
- Jul 2025
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of tetanus toxoid in systemic sclerosis (SSc), systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) (2 arms), sponsored by Leiden University Medical Center. Planned start Jul 2025; status: authorised.
02
Drugs
tetanus toxoid
03
Conditions
systemic sclerosis (SSc)systemic lupus erythematosus (SLE)rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2024-515312-50-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515312-50-00.